Anti-counterfeit foil for security packaging

Información del proyecto

ACfoil

Identificador del acuerdo de subvención: 651086

DOI

10.3030/651086

Proyecto cerrado

Fecha de la firma de la CE 29 Septiembre 2014

Fecha de inicio 1 Octubre 2014

Fecha de finalización 31 Marzo 2015

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

INMOLD AS
Denmark

Objetivo

Problem
More than one million people die each year from counterfeit medicines. 700,000 people in Africa die each year as victims of counterfeit malaria or tuberculosis drugs. The pain is not just financial – more than 200,000 jobs are lost due to counterfeiting in the US and Europe alone.

Solution – the innovation
Authenticity can be guaranteed by adding holograms to each individual box or bottle of medicine, but costs have so far been prohibitive. Inmold has found a way to mass-produce such holograms at least 100 times faster and 10 to 10,000 times cheaper than current state-of-the-art, and as a small and simple expansion of packaging equipment already commercially available. Inmold’s innovation can be both retrofitted and delivered with new equipment.

The project
Inmold has taken out four patents on the innovation, demonstrated a prototype with success with respect to parameters such as price and production speed, and established that there is an interesting market opportunity. However, since the pharma industry is quite conservative it is necessary to show customers customized designs as well as to get feedback from the market on sales and price models, implementation strategies and product features, which is the purpose of the project.

Business model
Inmold and Danapak has formed a collaboration where Inmold supplies production equipment and consultancy to Danapak using a licensing model with profit sharing. Danapak already supplies packaging equipment to the pharma industry and, hence, is a perfect partner for Inmold, who cannot approach the pharma market alone.

Customers and market
The pharma market is very large, yielding a significant packaging market volume of at least €700m. Danapak has a market penetration of 20-35%, depending on segment. Glaxo Smith Kline, Johnson & Johnson and LTS (Lohmann Therapie Systeme) have already shown a keen interest and will deliver feedback to Inmold during the project.

Ámbito científico (EuroSciVoc)

• ciencias médicas y de la salud › ciencias de la salud › enfermedad infecciosa › malaria
• ciencias naturales › ciencias químicas › ciencia de polímeros
• ciencias sociales › economía y empresa › gestión y empresas › modelo de negocio
• ciencias médicas y de la salud › medicina clínica › neumología › tuberculosis
• ciencias naturales › ciencias químicas › química inorgánica › metaloides

Programa(s)

• H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies PROGRAMA PRINCIPAL
  
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
  

Tema(s)

• NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs
  

Régimen de financiación

SME-1 - SME instrument phase 1

Convocatoria de propuestas

H2020-SMEInst-2014-2015

Coordinador

INMOLD AS

• Aportación neta de la UEn: € 50 000,00
• Dirección: TEGLBUEN 10 NIVEROD ; 2990 NIVA ; Dinamarca
• Pyme Sí:
  Región
  Danmark › Hovedstaden › Nordsjælland
• Región: Danmark › Hovedstaden › Nordsjælland
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 71 429,00